glp 1 va study Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort Frontiers | The therapeutic potential
Description
GIP""GIP IPFA-085POMC()2023
How theyre different and what it means for food businesses
UPDATED: 12:30 p.m
Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics
Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.
An analysis of PBM tension, the Newkirk litigation, Anthems GLP-1 coverage issues, and emerging risks in pharmacy benefit plan design.
